Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review

德诺苏马布 医学 特立帕肽 骨质疏松症 雷奈酸锶 雷洛昔芬 指南 系统回顾 内科学 物理疗法 梅德林 骨矿物 乳腺癌 癌症 法学 病理 雌激素受体 政治学
作者
Yi Wan,Fang Zeng,Haoyu Tan,Yanjiao Lu,Yonghui Zhang,Liheng Zhao,Ruxu You
出处
期刊:Osteoporosis International [Springer Nature]
卷期号:33 (5): 979-1015 被引量:12
标识
DOI:10.1007/s00198-021-06268-9
摘要

This paper systematically reviewed and assessed all retrievable pharmacoeconomic studies on denosumab for the treatment of osteoporosis. Denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the quality of pharmacoeconomic studies in osteoporosis.There are many pharmacoeconomic studies on denosumab for osteoporosis. However, the corresponding reviews are outdated or incomplete and need to be updated and refined. This article aims to systematically review and evaluate all retrievable pharmacoeconomic studies of denosumab for osteoporosis.A systematic literature search was performed utilizing PubMed, EMBASE(Ovid), Proquest(EconLit), Chongqing VIP, WanFang Database, and Chinese National Knowledge Infrastructure to identify full-text articles published before September 2021. The quality of full-text articles was evaluated by the Consolidated Health Economic Evaluation Reporting Standards(CHEERS) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases International Osteoporosis Foundation guideline(ESCEO-IOF).In total, 21 full-text articles were eligible for inclusion. Denosumab for postmenopausal osteoporosis was not dominant compared to zoledronate and teriparatide. However, denosumab was dominant compared with strontium ranelate, raloxifene, and ibandronate in patients over 65 years. The probabilities of denosumab being cost-effective or dominant were more than 85% compared with no treatment and risedronate in patients aged over 70 years. Compared to alendronate, the highest rate of denosumab dominance occurred in patients aged 65 to 75 years, at about 65%. Most of the articles had higher CHEERS scores than ESCEO-IOF scores (converted into percentages).The cost-effectiveness of denosumab for the treatment of osteoporosis was influenced by multiple factors. Generally, denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the transparency, generalization, and quality of pharmacoeconomic studies in osteoporosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
hsrlbc完成签到,获得积分10
3秒前
huvy完成签到 ,获得积分10
4秒前
虚幻元风完成签到 ,获得积分10
5秒前
changfox完成签到,获得积分10
7秒前
lilylwy完成签到 ,获得积分10
11秒前
小惠完成签到 ,获得积分10
12秒前
Ying完成签到,获得积分10
13秒前
天才小能喵完成签到 ,获得积分0
17秒前
三十四画生完成签到 ,获得积分10
18秒前
宗嘻嘻完成签到 ,获得积分10
20秒前
钟声完成签到,获得积分0
24秒前
Never stall完成签到 ,获得积分10
24秒前
xwl9955完成签到 ,获得积分10
26秒前
在阳光下完成签到 ,获得积分10
28秒前
年轻千愁完成签到 ,获得积分10
31秒前
多克特里完成签到 ,获得积分10
32秒前
nanfeng完成签到 ,获得积分10
33秒前
weiwei完成签到 ,获得积分10
35秒前
Ws完成签到 ,获得积分10
44秒前
yuqingqing发布了新的文献求助10
46秒前
651完成签到 ,获得积分10
47秒前
小绵羊完成签到 ,获得积分10
49秒前
江氏巨颏虎完成签到,获得积分10
51秒前
香草完成签到 ,获得积分10
59秒前
Ava应助非洲大象采纳,获得10
1分钟前
花园里的蒜完成签到 ,获得积分0
1分钟前
shuyu完成签到 ,获得积分10
1分钟前
充电宝应助呆头鹅鹅仔采纳,获得10
1分钟前
CipherSage应助Yong-AI-BUPT采纳,获得10
1分钟前
小夏完成签到 ,获得积分10
1分钟前
心流完成签到 ,获得积分10
1分钟前
JevonCheung完成签到 ,获得积分10
1分钟前
老王完成签到 ,获得积分10
1分钟前
合适的寄灵完成签到 ,获得积分10
1分钟前
纯情的远山完成签到,获得积分10
1分钟前
Jasper应助eden采纳,获得20
1分钟前
1分钟前
非洲大象发布了新的文献求助10
1分钟前
LQX2141完成签到 ,获得积分10
2分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068273
求助须知:如何正确求助?哪些是违规求助? 2722176
关于积分的说明 7476092
捐赠科研通 2369142
什么是DOI,文献DOI怎么找? 1256228
科研通“疑难数据库(出版商)”最低求助积分说明 609524
版权声明 596835